This study has set the basis for the development of a novel therapeutic approach aimed at advancing peripheral administration of vectorized anti-tau scFv: in the present work, we show that IM injection of anti-tau scFv antibodies has potential for the treatment of tauopathies. Here, MAPT is linked to tauopathy.